Conversation with The Cancer Letter

Conversation with The Cancer Letter

Friends’ Allen: Real-world endpoints can be used to fill evidence gaps about performance of medical products
Conversation with The Cancer LetterFreeReal-world Evidence

Friends’ Allen: Real-world endpoints can be used to fill evidence gaps about performance of medical products

If real-world endpoints are indeed accurate proxies for clinical trial endpoints, real-world endpoints should start to look increasingly similar to the clinical trial endpoints as more stringent criteria are applied, said Jeff Allen, president and CEO of Friends of Cancer Research.